Squarepoint
AST

Squarepoint’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Squarepoint’s Portfolio AST Stock Details AST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-15,690
Closed -$72K – 2216
2016
Q4 		$72K Buy
+15,690
New +$64.7K ﹤0.01% 1670
2015
Q3 		– Sell
-10,200
Closed -$47K – 703
2015
Q2 		$47K Buy
+10,200
New +$97.8K 0.02% 424

Other funds holding AST

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Squarepoint's AST Position: Q1 2017 in Review

Squarepoint sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q1 2017, closing a stake of 15,690 shares — an estimated $72K sold.

Squarepoint first reported a position in AST in Q2 2015 and held it in 2 quarters. The position peaked at $72K in Q4 2016. 66 funds tracked by Wall St. Rank hold AST as of Q1 2017.

  • Squarepoint reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q1 2017 after selling out during the quarter.
  • Squarepoint sold 15,690 Asterias Biotherapeutics Inc. Series A shares in Q1 2017, an estimated $72K.
  • Squarepoint first reported a position in Asterias Biotherapeutics Inc. Series A in Q2 2015 and held it in 2 quarters.
  • Squarepoint's Asterias Biotherapeutics Inc. Series A position peaked at $72K in Q4 2016.
  • 66 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q1 2017.

Based on Squarepoint's 13F filing for Q1 2017, filed 15 May 2017.